Effect of Paxirasol aerosol on the clinical condition and objective functional respiratory parameters of obstructive respiratory tract disease patients.
Paxirasol aerosol applied in daily 3 x 5-puff doses was well tolerated by the examined patients. In the course of the 21-day therapy the laboratory findings did not change-haemopoetic or liver injury was not observed. On two-thirds of the patients the amount of sputum decreased in response to Paxirasol aerosol but the symptoms accompanying expectoration did not change notably. Among the objective respiratory parameters FEV1 values increased and Rtot values decreased. These changes may be observed during the first third of therapy. There was a continuous and linear increase in FEV values characteristic of respiratory pressure conditions. This phenomenon is not characteristic alone of the changes of values of obstructive diseases patients. The authors recommend the use of Paxirasol aerosol for the treatment of respiratory tract disease patients.
Mészáros
L
L
First Department of Pulmonology, County Hospital-Outpatient Clinic, Zala County, Hungary.
Molnár
B
B
Beke
M
M
D000280:Administration, Inhalation; D001964:Bromhexine / Q000008:administration & dosage / Q000494:pharmacology / Q000627:therapeutic use*; D005260:Female; D006801:Humans; D008173:Lung Diseases, Obstructive / Q000188:drug therapy* / Q000503:physiopathology; D008875:Middle Aged; D012129:Respiratory Function Tests
D001964:Bromhexine